Literature DB >> 19582458

Oligo-secretory myeloma in a patient with ankylosing spondylitis.

Eva Perez-Pampin1, Joaquin Campos, Jorge Blanco, Manuel Perez-Encinas, Antonio Mera.   

Abstract

Non-secretory myeloma is a plasma cell dyscrasia characterized by the absence of serum and urinary monoclonal immunoglobulins on electrophoretic tests. Because of the lack of monoclonal protein, the identification of the disease is more difficult than for secretory myelomas. The coexistence of ankylosing spondylitis and multiple myeloma has been reported occasionally. We report a rare case of oligo-secretory myeloma coexistent with ankylosing spondylitis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19582458     DOI： 10.1007/s00296-009-1042-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  10 in total

Review 1.  Nonsecretory plasma cell myeloma--becoming even more rare with serum free light-chain assay: a brief review.

Authors:  Gene R Shaw
Journal:  Arch Pathol Lab Med       Date:  2006-08       Impact factor: 5.534

2.  Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.

Authors:  J Askling; L Klareskog; P Blomqvist; M Fored; N Feltelius
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

3.  Ankylosing spondylitis associated with IgA lambda chain myeloma.

Authors:  T W O'Neill; B J Harrison; A L Yin; P J Holt
Journal:  Br J Rheumatol       Date:  1997-03

4.  Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Authors:  M Drayson; L X Tang; R Drew; G P Mead; H Carr-Smith; A R Bradwell
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Cancer mortality following X-ray treatment for ankylosing spondylitis.

Authors:  H A Weiss; S C Darby; R Doll
Journal:  Int J Cancer       Date:  1994-11-01       Impact factor: 7.396

6.  [Association of non-secreting myeloma and ankylosing spondylitis. Considerations on a clinical case].

Authors:  M Gualandi; F Trotta; M Faggioli; A Vanini; M C Tassinari
Journal:  Minerva Med       Date:  1981-10-13       Impact factor: 4.806

7.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

8.  A molecular basis for nonsecretory myeloma.

Authors:  Daniel Coriu; Kristal Weaver; Maria Schell; Manfred Eulitz; Charles L Murphy; Deborah T Weiss; Alan Solomon
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

9.  Ankylosing spondylitis and monoclonal gammopathies.

Authors:  G Renier; J C Renier; M Gardembas-Pain; A Chevailler; M Boasson; D Hurez
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

10.  Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study.

Authors:  N Feltelius; A Ekbom; P Blomqvist
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103
  10 in total
  1 in total

Review 1.  Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Alexei Shimanovsky; Juliana Alvarez Argote; Shruti Murali; Constantin A Dasanu
Journal:  BBA Clin       Date:  2016-05-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.